BGI Co-Win

Aijie Boya is a medical instrument and magnetic solid-phase material company.

LeadBio Tech is a biotechnology company focused on developing bioartificial blood vessel medical devices. It specializes in tissue engineering and regeneration solutions to replace and repair human tissues and organs. The company's flagship product is degradable bioartificial blood vessels based on skeleton immune wrapping technology, designed for use in arteriovenous grafts (AVG) surgeries. These advanced artificial vessels aim to improve patient outcomes by providing superior alternatives to traditional vascular access methods.

Burning Point Medical is a pharmaceutical company focused on developing solutions for hypertensive and spastic pain disorders. The firm specializes in creating products that aim to effectively treat hypertension and alleviate symptoms such as chest pain and spastic pains. By providing targeted treatments, Burning Point Medical enables healthcare professionals to offer more effective therapeutic options to their patients, ultimately enhancing patient care in these critical areas.

Waker Biology is a developer of a platform designed to evaluate the safety of gene therapy. The company focuses on high-precision CRISPR/Cas9 quantitative off-target analysis, vector copy number assessment, vector quality control, immune repertoire analysis, and efficient sgRNA screening. Waker Biology provides a comprehensive suite of personalized services that includes sample acceptance and report submission, catering to the diverse needs of its clients in the field of gene therapy safety evaluation.

Yingshu Life is a producer and supplier of medical endoscope systems and devices. They offer solutions for general surgery, urology, gynecology, gastroenterology and pulmonology with a portfolio including rigid endoscope systems, single-use flexible endoscopes, and endoscopic accessories.

Ubrigene is driven by the advancement of gene and cell therapy technologies through research and development represented by AAV vectors. It can provide a comprehensive solution for gene therapy industrialization.

Hemu Gene Biotechnology is a company specializing in gene therapy technology to treat hemoglobin diseases. With independent research and development capabilities and a reliable quality management system, Hemu Gene focuses on studying, creating, and utilizing gene therapy vectors and genetic engineering technologies. The company employs two main gene editing platforms: lentivirus and CRISPR/Cas. Additionally, Hemu Gene has established hematopoietic stem cell gene therapy production lines and is actively involved in international clinical collaborations and registration processes for its therapies.

YZY Bio is a biotechnology company focused on the development of bispecific antibody-based therapies aimed at treating cancer and cancer-associated complications, as well as age-related ophthalmologic diseases. By leveraging advancements in molecular biology, YZY Bio creates innovative anti-tumor bispecific antibodies that provide more effective treatment options for patients facing significant medical challenges. The company operates primarily in one segment, which encompasses the discovery, development, and commercialization of a new class of anti-tumor medicines. YZY Bio generates most of its revenue from the People's Republic of China, addressing critical medical needs in oncology and ophthalmology.

Ab&B Biotech focuses on the research and development of innovative human vaccines and multivalent vaccines.

OkayBio is a biotechnology company focusing on the research and development of In vitro diagnostic products. OkayBio's products are IVD markers involved in multiple fields, such as infection, cardiovascular disease, renal function, and oncology.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

ToloBio develops molecular diagnostics solutions for pathogen detection, disease screening, and precision medicine.

Targene Medical concentrates on the study, creation, and distribution of tools for accurate and early cancer diagnosis. It is dedicated to entire cancer diagnostic and treatment process. It provides research and development of early detection tools for one type of cancer, multiple types of cancer, and even all cancers.

F&S Pharmatech is a pharmaceutical technology company based in Nanjing, China, specializing in the development of differentiated generic drugs and pharmaceutical intermediates. The company is engaged in the research and development of advanced pharmaceutical chemicals, including notable products such as sacubitril and diphenyl piperidine methanol. F&S Pharmatech offers contract manufacturing organization (CMO) services, alongside providing intellectual property solutions and environmentally friendly chemical technologies. Its focus on delivering reliable products supports research and development centers and generic drug developers, aiming to shorten development cycles and reduce product costs within the healthcare industry.

Cellnuo develops pharmaceutical products to help patients reduce the incidence of hypoglycemia and maintain healthier blood glucose levels, improving health outcomes for patients.

Ascentawits Pharmaceuticals Ltd. is a biotechnology company founded in 2014 and headquartered in Shenzhen, China. The firm specializes in the development of anti-tumor drugs, particularly focusing on small molecule targeted conjugated therapies. Ascentawits employs innovative drug design and screening techniques that leverage specific tumor micro-environments to create effective treatments for cancer patients. Through its research and development efforts, the company aims to improve therapeutic options for individuals battling various forms of cancer.